Xiaolong Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11596424/publications.pdf

Version: 2024-02-01

| 16 | 354 | 9 | 14 |
|----------|----------------|--------------|----------------|
| papers | citations | h-index | g-index |
| 17 | 17 | 17 | 522 |
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma. Neuro-Oncology, 2022, 24, 1712-1725. | 1.2 | 8 |
| 2 | PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro-Oncology, 2021, 23, 920-931. | 1.2 | 58 |
| 3 | The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab015. | 0.7 | 16 |
| 4 | <i>EGFR</i> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clinical Cancer Research, 2020, 26, 1395-1407. | 7.0 | 26 |
| 5 | Tie2–FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Research, 2019, 79, 5088-5101. | 0.9 | 17 |
| 6 | Wild-type defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs. American Journal of Cancer Research, 2019, 9, 1734-1745. | 1.4 | 3 |
| 7 | BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening. American Journal of Cancer Research, 2019, 9, 2428-2441. | 1.4 | 1 |
| 8 | DDIS-03. EGFR AMPLIFICATION INDUCED INCREASED DNA DAMAGE RESPONSE AND PREDICTED SELECTIVE SENSITIVITY TO TALAZOPARIB (PARP INHIBITOR) IN GLIOBLASTOMA STEM-LIKE CELLS. Neuro-Oncology, 2018, 20, vi69-vi69. | 1.2 | 0 |
| 9 | EXTH-11. GLIOBLASTOMA STEM CELL GROWTH DEPENDENCE ON NUTRIENTS: MORE THAN BASAL METABOLIC ACTIVITIES. Neuro-Oncology, 2018, 20, vi87-vi87. | 1.2 | O |
| 10 | Molecular Aberrance in Papillary Thyroid Microcarcinoma Bearing High Aggressiveness: Identifying a "Tibetan Mastiff Dog―From Puppies. Journal of Cellular Biochemistry, 2016, 117, 1491-1496. | 2.6 | 10 |
| 11 | Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma. International Journal of Clinical Oncology, 2014, 19, 800-804. | 2.2 | 9 |
| 12 | Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma. Oncology Letters, 2013, 5, 1412-1416. | 1.8 | 14 |
| 13 | Achieving cell penetration with distance-matching cysteine cross-linkers: a facile route to cell-permeable peptide dual inhibitors of Mdm2/Mdmx. Chemical Communications, 2011, 47, 9396. | 4.1 | 79 |
| 14 | Conjugation of spermine enhances cellular uptake of the stapled peptide-based inhibitors of p53-Mdm2 interaction. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7412-7415. | 2.2 | 14 |
| 15 | Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1472-1475. | 2.2 | 97 |
| 16 | Multi-analysis with mathematic model of 3125 non-thyrogenous masses of the neck. Chinese-German Journal of Clinical Oncology, 2008, 7, 319-325. | 0.1 | 0 |